Asimov, a startup using computer-aided biology engineering design, announced today that it has raised $4. 7 million seed funding in a round led by Andreessen Horowitz, with the participation of Data Collective, Pillar and AME Cloud Ventures.
“In nature, biology has evolved into sophisticated genetic circuits to do amazing things like self-organize into multicellular patterns, construct atomic-precise materials, and protect against disease. However, genetic circuits are not currently being harnessed in biotechnology because engineering them is a technical challenge. Solving this problem would unlock advanced biotechnology that appears to be science fiction: smart therapists that sense and respond to disease, molecular assembly lines for biomanufacturing, and living materials that heal and adapt to their environment,” said Alec Nielsen, Ph.D. D. D. , co-founder and chief executive officer; ‘Asimov products are custom-built genetic circuits: DNA sequences that encode new cellular functions. Our circuits enable customers to develop next-generation biotechnology in the fields of health, manufacturing and consumer goods This seed funding enables us to quickly scale up and partner with customers in a variety of areas. “That’s right.
Asimov’s software and genetics platform was originally developed by the Massachusetts Institute of Technology and Boston University. Funded by the Office of Naval Research and Defense Advanced Research Projects Agency (DARPA), the research has been published in Science, Nature Methods and Nature Chemical Biology. The industry-grade version of the platform combines state-of-the-art synthetic biology, biophysical simulations and machine learning design.
“Asimov’s approach to engineering biology has transformative potential across a number of areas that touch and improve people’s lives. We’re thrilled to partner with the Asimov team,” said Vijay Pande, Ph.D. D. D. , Managing Partner of Andreessen Horowitz “Just as semiconductor companies today rely on electronic design automation to build their chips, computer-aided design plays an increasingly important role in bioengineering. We have reached an inflection point in terms of what can be reliably built It has profound implications “That’s right.
AMOUT ASIMOV Asimov empowers the creation of previously impossible biotechnology The design platform of the company enables them to precisely engineer genetic circuits for customers in a variety of sectors. The company was founded by four pioneers of biological engineering, Professor Christopher Voigt of the Massachusetts Institute of Technology, Professor Douglas Densmore of Boston University, and Ph.D. MIT of Biological Engineering. D. D. Alec Nielsen and Raja Srinivas Visit www for more information Asimov; Oh, Io
Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/Asimov/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at contact@investocracy.co
